Novo Nordisk shares plunge 20% after disappointing trial results; …
Dec 20, 2024 · Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point Friday after reporting trial results that missed expectations.
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · The data from Novo's CagriSema Phase III trial was based on about 3,400 people with a body mass index (BMI) of 30 or above or people with a BMI of 27 and at least one weight-related comorbidity ...
What went wrong with Novo Nordisk’s CagriSema obesity drug trial
5 days ago · The phase three trial for CagriSema involved around 3,400 participants with obesity or those who were overweight with one or more comorbidities and lasted for 68 weeks. The study followed a flexible protocol, enabling patients to adjust their dosage throughout. By the trial’s conclusion, just 57.3% of those on CagriSema reached the highest dose.
Novo Nordisk A/S: CagriSema demonstrates superior weight
Dec 20, 2024 · In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · The 68-week study showed participants on CagriSema lost about 23% of their body weight, compared with 12% for those taking cagrilintide by itself, 16% for those on semaglutide, and 2.3% for people ...
Novo Nordisk's CagriSema Shows Superior, But Lower-than …
Dec 20, 2024 · After 68 weeks, 57.3 percent of patients treated with CagriSema were on the highest dose, compared to 82.5 percent with cagrilintide 2.4 mg and 70.2 percent with semaglutide 2.4 mg.
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
Dec 20, 2024 · In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with ...
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · The Danish company is now in late-stage testing with a dual-acting experimental drug it calls cagrisema. The drug combines semaglutide, the active ingredient in Wegovy, with another compound that mimics a metabolic hormone called amylin.
Novo Nordisk affirms 25% weight-loss expectation for …
Nov 6, 2024 · Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new...
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles …
Dec 20, 2024 · CagriSema is a weekly injection combining semaglutide, which is the active ingredient in its blockbuster drug Wegovy and mimics the gut hormone GLP-1, with a separate molecule called cagrilintide ...